Overview

Photocil (Topical) for the Treatment of Psoriasis Vulgaris

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
0
Participant gender:
All
Summary
Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the safety and efficacy of Photocil in the treatment of psoriasis
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Applied Biology, Inc.
Treatments:
Sunscreening Agents
Criteria
Inclusion Criteria:

- Diagnosed with psoriasis vulgaris confirmed by a dermatologist

- Psoriasis lesions affecting at a minimum 5% of the facial, legs, or arms surface area

- Age: 18 to 65

- Participants able to give informed consent

Exclusion Criteria:

- Subject did not respond to prior phototherapy treatment

- Subject completed phototherapy for same lesion(s) in last 6 months

- Subject has previous history of skin cancer

- Subject has previous history of photosensitivity

- Subject has a history of herpes (HSV I or II) outbreaks

- Subject has previous history of autoimmune disease may be excluded at investigator's
discretion

- Subject is currently taking of immunosuppressive or photosensitizing drugs

- Subject plans to use antibiotics, anti-fungal, calcineurin inhibitors or other drugs
that may cause photosensitivity during the study period. These patients may be
excluded at investigator's discretion

- Subject is pregnant or lactating women